Bisphosphonates as potential adjuvants for patients with cancers of the digestive system

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Best known for their anti-resorptive activity in bone, bisphosphonates (BPs) have generated interest as potential antineoplastic agents given their pleiotropic biological effects which include antiproliferative, antiangiogenic and immune-modulating properties. Clinical studies in multiple malignancies suggest that BPs may be active in the prevention or treatment of cancer. Digestive tract malignancies represent a large and heterogeneous disease group, and the activity of BPs in these cancers has not been extensively studied. Recent data showing that some BPs inhibit human epidermal growth factor receptor (HER) signaling highlight a potential therapeutic opportunity in digestive cancers, many of which have alterations in the HER axis. Herein, we review the available evidence providing a rationale for the repurposing of BPs as a therapeutic adjunct in the treatment of digestive malignancies, especially in HER-driven subgroups.

Original languageEnglish
Pages (from-to)906-916
Number of pages11
JournalWorld Journal of Gastroenterology
Issue number3
StatePublished - 21 Jan 2016


  • Bisphosphonates
  • Cancer
  • Gastrointestinal
  • Hepatobiliary
  • Human epidermal growth factor


Dive into the research topics of 'Bisphosphonates as potential adjuvants for patients with cancers of the digestive system'. Together they form a unique fingerprint.

Cite this